These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 36359347)

  • 1. The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints.
    Giuffrida P; Celsa C; Antonucci M; Peri M; Grassini MV; Rancatore G; Giacchetto CM; Cannella R; Incorvaia L; Corsini LR; Morana P; La Mantia C; Badalamenti G; Brancatelli G; Cammà C; Cabibbo G
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRECIST for HCC: Performance and novel refinements.
    Llovet JM; Lencioni R
    J Hepatol; 2020 Feb; 72(2):288-306. PubMed ID: 31954493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
    Llovet JM; Montal R; Villanueva A
    J Hepatol; 2019 Jun; 70(6):1262-1277. PubMed ID: 30943423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights.
    Cammarota A; Zanuso V; Pressiani T; Personeni N; Rimassa L
    J Hepatocell Carcinoma; 2022; 9():1011-1027. PubMed ID: 36128575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?
    Celsa C; Cabibbo G; Enea M; Battaglia S; Rizzo GEM; Busacca A; Giuffrida P; Stornello C; Brancatelli G; Cannella R; Gruttadauria S; Cammà C
    Liver Int; 2021 May; 41(5):1105-1116. PubMed ID: 33587814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
    Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Busacca A; Matranga D; Attanasio M; Reig M; Craxì A; Cammà C
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies.
    Kudo M; Montal R; Finn RS; Castet F; Ueshima K; Nishida N; Haber PK; Hu Y; Chiba Y; Schwartz M; Meyer T; Lencioni R; Llovet JM
    Clin Cancer Res; 2022 Aug; 28(16):3443-3451. PubMed ID: 34907081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Huang L; Kang D; Zhao C; Liu X
    Sci Rep; 2024 Feb; 14(1):4327. PubMed ID: 38383730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
    Front Immunol; 2022; 13():913464. PubMed ID: 35677059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma.
    Jin Y; Ren H; Yue Q; Wu W; Liu C; Guo Y; Zhao P
    BMC Cancer; 2024 Feb; 24(1):258. PubMed ID: 38395854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.
    Lim M; Muquith M; Miramontes B; Lee CJ; Espinoza M; Huang YH; Hsiehchen D
    Hepatology; 2023 Dec; 78(6):1755-1762. PubMed ID: 37254559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.
    Zhang Z; Pan Q; Lu M; Zhao B
    EClinicalMedicine; 2023 Sep; 63():102156. PubMed ID: 37600482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses.
    Zhang J; Liang W; Liang H; Wang X; He J
    Ann Transl Med; 2019 Jun; 7(11):244. PubMed ID: 31317014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma.
    Li YF; Wang Y; Zhou J; Wei YC; Lin J; Yin YX; Chen GM; Zhang FY; Chen S; Zhou ZW; Chen YB; Cong Nie R
    World J Oncol; 2022 Jun; 13(3):126-135. PubMed ID: 35837321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
    Lencioni R; Montal R; Torres F; Park JW; Decaens T; Raoul JL; Kudo M; Chang C; Ríos J; Boige V; Assenat E; Kang YK; Lim HY; Walters I; Llovet JM
    J Hepatol; 2017 Jun; 66(6):1166-1172. PubMed ID: 28131794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy-Based Treatments of Hepatocellular Carcinoma:
    Cannella R; Lewis S; da Fonseca L; Ronot M; Rimola J
    AJR Am J Roentgenol; 2022 Oct; 219(4):533-546. PubMed ID: 35506555
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.